secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2026-06-11T11:04:42+00:00
Accession:  0001628280-26-042365
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4T Phase 1 cemsidomide in RRMM shows 53% ORR at RP2D, MRD negativity, well-tolerated
--------------------------------------------------------------------------------

- 53% ORR at 100 µg RP2D; 36% ORR across all doses (73 patients, median 7 prior lines).
- MRD negativity achieved in two patients at RP2D (sCR and CR); responses deepened over time.
- Median PFS 3.9 months (95% CI 3.2–5.6); median DOR 7.9 months (95% CI 3.0–NE).
- No treatment discontinuations related to cemsidomide; manageable neutropenia (58% Grade 3/4).
- ORR consistent across subgroups: prior CAR-T/TCE 53% at RP2D; prior BCMA 47% at RP2D.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/0001628280-26-042365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828026042365/cccc-20260611.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-042365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer